For research use only. Not for therapeutic Use.
Axitinib, also known as AG013736, is an orally bioavailable tyrosine kinase inhibitor. Axitinib inhibits the proangiogenic cytokines vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor (PDGF), thereby exerting an anti-angiogenic effect. A xitinib has received FDA (27 January 2012), EMA (13 September 2012), MHRA (3 September 2012) and TGA (26 July 2012) approval for use as a treatment for renal cell carcinoma.
| Catalog Number | A000203 |
| CAS Number | 319460-85-0 |
| Synonyms | AG 013736 |
| Molecular Formula | C₂₂H₁₈N₄OS |
| Purity | ≥95% |
| Target | VEGFR |
| Solubility | >19.3mg/mL in DMSO |
| Storage | -20°C |
| InChI | InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+ |
| InChIKey | RITAVMQDGBJQJZ-FMIVXFBMSA-N |
| SMILES | CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=NN3)C=CC4=CC=CC=N4 |
| Reference | 1: Chen Y, Tortorici MA, Garrett M, Hee B, Klamerus KJ, Pithavala YK. Clinical |
